NDLI: Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Halpern, Bruno Halpern, Alfredo
Spatial Coverage	United States
Description	Country affiliation: Brazil Author Affiliation: Halpern B ( Hospital das Clínicas da Universidade de São Paulo, Department of Endocrinology and Metabology, Obesity Group , 462 cj 72-73, 7h floor, São Paulo-SP, CEP 05410-000 , Brazil brunohalpern@hotmail.com.)
Abstract	INTRODUCTION: Options for treating obesity remain limited despite it being a chronic, recurrent and morbid condition. New drugs that are proposed for its treatment encounter strong reluctance by regulatory agencies and many doctors. AREAS COVERED: This review will focus on the safety of an older drug, orlistat (the only one still approved in the European Union) and a newer recently FDA-approved one, lorcaserin. Both are approved as long-term monotherapy for obesity in the United States of America and they have demonstrated median weight loss of nearly 3% over placebo. EXPERT OPINION: Research, development and approval of new anti-obesity drugs are necessary for improved management of this chronic condition. Orlistat and lorcaserin are two FDA-approved drugs with limited overall efficacy. Nevertheless they are useful weapons for at least some obese individuals. Orlistat has a long and solid safety profile, whereas the safety of lorcaserin is still a matter of debate, mainly due to a lack of long-term data. However, lorcaserin's selective agonism on 5HT2c serotonin receptors diminishes concerns about valvulopathy associated with other serotonin agonists, such as fenfluramine.
File Format	HTM / HTML
ISSN	14740338
Issue Number	2
Volume Number	14
e-ISSN	1744764X
Journal	Expert Opinion on Drug Safety
Language	English
Publisher	Taylor & Francis
Publisher Date	2015-02-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Anti-obesity Agents Adverse Effects Benzazepines Lactones Drug-induced Liver Injury Drug Interactions Heart Valve Diseases Chemically Induced Humans Malabsorption Syndromes Neoplasms Serotonin Syndrome United States United States Food And Drug Administration Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Orlistat associated with hypertension.

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt.

FDA warns Merck over its promotion of rofecoxib.

Risk of colorectal cancer after initiation of orlistat: matched cohort study

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink

Two anti-obesity hopefuls and their safety.

Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Lorcaserin Hcl for the treatment of obesity.

Parasite-Based Screening and Proteome Profiling Reveal Orlistat, an FDA-Approved Drug, as a Potential Anti Trypanosoma brucei $Agent^{[†]}$

Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.

Similar Documents

Orlistat associated with hypertension.

Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt.

FDA warns Merck over its promotion of rofecoxib.

Risk of colorectal cancer after initiation of orlistat: matched cohort study

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink

Two anti-obesity hopefuls and their safety.

Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Lorcaserin Hcl for the treatment of obesity.

Parasite-Based Screening and Proteome Profiling Reveal Orlistat, an FDA-Approved Drug, as a Potential Anti Trypanosoma brucei $Agent^{[†]}$

Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.